NOXOPHARM LIMITED — Investor Presentation 2017

Mar 9, 2017

==> picture [180 x 76] intentionally omitted <==

10 March 2017 Sydney, Australia

ASX: NOX

Gold Coast Qld Mid-year Briefing

Noxopharm Limited

ABN 50 608 966 123

Registered Office: Suite 1 Level 6 50 Queen St Melbourne VIC 3000 Australia

Operations Office: Suite 3 Level 4 828 Pacific Hwy Gordon NSW 2072 Australia

In addition to the Melbourne and Sydney mid-year shareholder briefings, Noxopharm Limited now invites shareholders and interested parties to attend a Company briefing on:

• the Company’s formal clinical trial program

• a NOX66 compassionate use scheme for rare cancers and cancers where patients have no access to formal studies

• the Company’s expanding non-oncology drug program.

Tuesday June 6[th] from 1.30-3.00pm

at

Board of Directors

Mr Peter Marks Chairman Non-Executive Director

Surfers Paradise Marriott Resort Hotel

158 Ferny Ave, Surfers Paradise, Queensland

Dr Graham Kelly Chief Executive Officer Managing Director

Dr Ian Dixon Non-Executive Director

Please contact Prue Kelly for registration and details: info@noxopharm.com 02-91442223

About NOX66

NOX66 is an innovative dosage formulation of the experimental anti-cancer drug, idronoxil, developed specifically to protect idronoxil from being inactivated in the human body by Phase 2 metabolism. The purpose is to ensure that most idronoxil administered remains in an active form rather than as inactive Phase 2 metabolites.

Idronoxil works by cancelling mechanisms (such as PARP1/Akt) in cancer cells that allow those cells to resist the killing effects of chemotherapies and radiotherapy. Idronoxil targets an external NADH oxidase, ENOX 2, responsible for maintaining the transmembrane electron potential (TMEP) in the plasma membrane. Inhibition of this enzyme causes loss of TMEP and disruption of key downstream pro-survival mechanisms including PARP1/Akt/PI3 kinase. ENOX2 is an oncogene whose expression is restricted to cancer cells.

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney and Melbourne. The Company has a primary focus on the development of drugs to address the problem of drugresistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.

INVESTOR AND MEDIA ENQUIRIES: Prue Kelly E: info@noxopharm.com T: + 61 2 9144 2223

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.